{"filing":{"accession_number":"0001104659-26-072382","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"tm2617224d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926072382/tm2617224d1_8k.htm"},"events":[{"id":5607,"run_id":4918,"accession_number":"0001104659-26-072382","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Humacyte disclosed presentation of Phase 3 clinical trial results (V012) for its ATEV product in arteriovenous access for hemodialysis patients on June 10, 2026. While this is a significant clinical milestone for a medical device company, the disclosure does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The clinical trial readout is material to investors assessing the company's pipeline and regulatory prospects, warranting classification as other_material.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5918,"accession_number":"0001104659-26-072382","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Humacyte disclosed presentation of Phase 3 clinical trial results (V012) for its ATEV product in arteriovenous access for hemodialysis patients on June 10, 2026. While this is a significant clinical milestone for a medical device company, the disclosure does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The clinical trial readout is material to investors assessing the company's pipeline and regulatory prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:36:17.051525+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5918,"accession_number":"0001104659-26-072382","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Humacyte disclosed presentation of Phase 3 clinical trial results (V012) for its ATEV product in arteriovenous access for hemodialysis patients on June 10, 2026. While this is a significant clinical milestone for a medical device company, the disclosure does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The clinical trial readout is material to investors assessing the company's pipeline and regulatory prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:36:17.051525+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-10"}]}